(4aR,7S,10S,13S)-10,13-ジベンジル-7-[6-オキソ-6-[(S)-オキシラニル]ヘキシル]-1,2,3,4,9,10-ヘキサヒドロ-4aH-6,9,12,14a-テトラアザベンゾシクロドデセン-5,8,11,14(6H,7H,12H,13H)-テトラオン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H301：飲み込むと有毒

• 注意書き

  P301+P310：飲み込んだ場合：直ちに医師に連絡すること。

(4aR,7S,10S,13S)-10,13-ジベンジル-7-[6-オキソ-6-[(S)-オキシラニル]ヘキシル]-1,2,3,4,9,10-ヘキサヒドロ-4aH-6,9,12,14a-テトラアザベンゾシクロドデセン-5,8,11,14(6H,7H,12H,13H)-テトラオン 価格

(4aR,7S,10S,13S)-10,13-ジベンジル-7-[6-オキソ-6-[(S)-オキシラニル]ヘキシル]-1,2,3,4,9,10-ヘキサヒドロ-4aH-6,9,12,14a-テトラアザベンゾシクロドデセン-5,8,11,14(6H,7H,12H,13H)-テトラオン 化学特性,用途語,生産方法

• 説明

  Trapoxin A is a cyclotetrapeptide histone deacetylase (HDAC) inhibitor. It inhibits HDAC activity in a concentration-dependent and irreversible manner. Trapoxin A inhibits proliferation of NIH3T3 cells transformed by the oncogene v-sis (sis/NIH3T3; IC₅₀ = ~200 ng/ml) and has detransformation activity, flattening sis/NIH3T3 cells when used at a concentration of 1 ng/ml. It also halts the cell cycle at the G₂ phase in 3Y1 fibroblasts when used at a concentration of 10 nM and inhibits growth of TR303 cells resistant to trichostatin A at a concentration of 50 ng/ml.

• 使用

  Trapoxin A has been used:
  
  • to study its effects on the inhibition of histone deacetylase 11 (HDAC11)
  • to study its effects on the inhibition of HDAC3 in human cell lines
  • to study its effects on the inhibition of HDAC6 in rat pyramidal neurons
  
  

• 定義

  ChEBI: A homodetic cyclic tetrapeptide constructed from L-phenylalanyl (x2), D-pipecolinyl and L-2-amino-8-oxo-9,10-epoxydecanoyl residues.

(4aR,7S,10S,13S)-10,13-ジベンジル-7-[6-オキソ-6-[(S)-オキシラニル]ヘキシル]-1,2,3,4,9,10-ヘキサヒドロ-4aH-6,9,12,14a-テトラアザベンゾシクロドデセン-5,8,11,14(6H,7H,12H,13H)-テトラオン 生産企業

Global(8)Suppliers

133155-89-2, (4aR,7S,10S,13S)-10,13-ジベンジル-7-[6-オキソ-6-[(S)-オキシラニル]ヘキシル]-1,2,3,4,9,10-ヘキサヒドロ-4aH-6,9,12,14a-テトラアザベンゾシクロドデセン-5,8,11,14(6H,7H,12H,13H)-テトラオン キーワード